COMMUNIQUÉS West-GlobeNewswire

CGA.vitaslim Announces Mission to Help 5,000 Adults Combat the "Three Highs" and Reclaim Their Health and Wealth in Hong Kong
23/06/2026
HONG KONG, June 23, 2026 (GLOBE NEWSWIRE) -- CGA.vitaslim, a premier health and wellness consultancy, today announced the launch of a new community-focused initiative aimed at helping 5,000 individuals aged 30 to 60 [...]
Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
23/06/2026
ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission Orion Corporation (Orion Pharma) today [...]
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
23/06/2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution [...]
Transactions in connection with share buy-back program
23/06/2026
Company announcement no. 22 - 26 23 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Communiqué de presse : Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire
23/06/2026
Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire Wayrilz est un inhibiteur de la BTK qui agit par modulation multi-immune pour aider à traiter les causes sous-jacentes de la [...]
BienRaíz Launches Vitamin D3 5000 IU Softgels: A High-Potency, Simple Formula for Everyday Wellness
23/06/2026
New Vitamin D3 Supplement Delivers 5000 IU of Cholecalciferol in Easy-to-Take Softgels Designed for Adults Seeking a Flexible Daily Wellness Routine LOS ANGELES, June 23, 2026 (GLOBE NEWSWIRE) -- As more adults spend [...]
argenx to Host Autoimmune Myositis R&D Webinar
23/06/2026
June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a [...]
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
23/06/2026
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant advancement for people [...]
Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes
23/06/2026
Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes Cenrifki représente une avancée [...]
Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company
23/06/2026
Press Release Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company Shareholder loan agreement for up to €6.0 million over 3 years Company is currently well-financed, [...]
Nicox et Vester Finance signent une convention d’avance en compte courant d’actionnaire en support des activités stratégiques de la Société
23/06/2026
Communiqué de presse Nicox et Vester Finance signent une convention d’avance en compte courant d’actionnaire en support des activités stratégiques de la Société Convention d’avance en compte courant d’actionnaire pour [...]
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
23/06/2026
Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval [...]
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
23/06/2026
TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) announced the next steps in connection with changes to the Company’s share capital [...]
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/06/2026
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Pioneering screening test offers potential to find more aggressive prostate cancers
22/06/2026
Annals of Internal Medicine publishes study showing potential benefits of Stockholm3 in identifying patients with aggressive prostate cancer STOCKHOLM, June 22, 2026 (GLOBE NEWSWIRE) -- A3P Biomedical, a diagnostics [...]
Flyte Partners with GSE Worldwide and PGA TOUR Professional Emiliano Grillo, Debuted at the 2026 U.S. Open
22/06/2026
Partnership positions Flyte within elite professional sports ecosystem through leading talent agency GSE Worldwide Collaboration highlights growing demand for efficient regional travel solutions among professional [...]
Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders
22/06/2026
TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the “ [...]
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
22/06/2026
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, [...]
Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
22/06/2026
First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa, Florida Global multi-site study includes locations in U.S., Korea, the UK, Spain, and France Study [...]

Pages